Intervention

LDV/SOF

ClinicalTrials.gov intervention label

Clinical trials4

Recruiting0

Common conditions6

Lead sponsors shown1

Clinical trials

4 shown

Efficacy, Safety, and Tolerability of Ledipasvir/Sofosbuvir (LDV/SOF) Treatment for HIV/HCV Co-infected Participants Who Switch to Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) or Emtricitabine/Rilpivirine/Tenofovir Alafenamide (F/R/TAF) Prior to LDV/SOF HCV TreatmentNCT02707601 · 2016-04-01

Safety and Efficacy of Ledipasvir/Sofosbuvir in Adults With Chronic HCV InfectionNCT02472886 · 2015-06-17

Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed-Dose Combination (FDC) for 6 Weeks in Adults With Acute Genotype 1 or 4 Hepatitis C Virus (HCV) and Chronic Human Immunodeficiency Virus (HIV)-1 Co-InfectionNCT02457611 · 2015-06-01

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 or 4 HCV and HIV-1 Co-infectionNCT02073656 · 2014-02-01

Common conditions

HCV Infection1 Hepatitis C Infection With HIV Co-Infection1 Hepatitis C Virus1 Hepatitis C Virus Infection1 HIV1 HIV-1 Infection1

Leading sponsors

Gilead Sciences4

Trial status mix

COMPLETED4

Phase mix

PHASE33

PHASE21

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.